BioWorld

July 17, 2009

The 'Rights' Stuff: Offering Gains Pharmacyclics $24M

Rebounding from its 2007 troubles with lung cancer drug Xcytrin, Pharmacyclics Inc. has emerged with a retooled management team, a multiproduct pipeline and a rather unusual - at least for biotech - money-raising strategy. (BioWorld Today) Read More

Amgen to Face Bundling Hits; CMS Rule Tolerable for Others

Tysabri Sales Stay Strong in a Good Biogen Quarter

NewCo News: AngioChem Crossing Barriers in Efforts to Heal the Brain

BDSI's Cancer Pain Film Onsolis Wins FDA OK

Clinic Roundup

Appointments And Advancements

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...